G-protein-coupled receptors (GPCR) participate in many disease pathways and represent the largest family of therapeutic targets. Thus, great investments are made to discover drugs modulating GPCR-mediated events. Among functional assays for screening GPCRs, the Transfluor ® imaging assay is based on redistribution of cytosolic β-arrestin to an activated GPCR and has become widely used in high-content screening. However, assessing Transfluor ® alone has limitations: relying on a single mechanistic step of β-arrestin redistribution during GPCR activation, providing no information on the stimulated GPCR's intracellular fate, and using only a single fluorescent color (green fluorescent protein). Taking full advantage of high-content imaging to screen approximately 2000 compounds, the authors multifplexed the Transfluor ® assay with an immunofluorescence-based quantification of GPCR internalization. This approach identified and classified 377 compounds interfering with agonistinduced activation of the Transfluor ® assay, receptor internalization, or both. In addition, a subset of compounds was analyzed for their performance across imaging, cell-based calcium release (fluorometric imaging plate reader [FLIPR]), and biochemical receptor binding assays (scintillation proximity assay). This indicated that the imaging assays have even better predictive power for direct inhibition of receptor binding than the FLIPR assay. In conclusion, compounds inducing unique responses can suggest novel mechanisms of action and be used as tools to study GPCR activation and internalization. (Journal of Biomolecular Screening 2008:449-455) 
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs) are a large family of membrane proteins offering excellent targets for therapeutic drugs. 1 Agonist-induced activation of GPCRs at the plasma membrane leads to a cascade of intracellular events. These events depend on a receptor-specific G-protein-coupling mechanism and a cell-specific protein complement. 2 Following activation of Gprotein-initiated signaling at the plasma membrane, GPCRs undergo desensitization through mechanisms involving phosphorylation and/or internalization of the receptor. G-protein-coupled receptor kinases (GRKs) phosphorylate the GPCR tail, allowing recruitment of β-arrestin to the ligand-receptor complex. β-arrestin directly interacts with clathrin, beginning the process of internalization by redistributing the GPCR-ligand complex to clathrin-coated pits. 3 Once in coated pits, GPCRs are internalized into early endosomes and subsequently found in endosomal vesicles. Depending on GPCR class, β-arrestin may (class B) or may not (class A) remain associated with the receptor in the endosomes. 4 Within the endosome, the receptor can be dephosphorylated and recycled back to the cell surface for additional ligand stimulation or be targeted to lysosomal vesicles for degradation. As the ligand-bound receptor recruits arrestin and moves from coated pits through different vesicular compartments, it initiates and participates in the assembly of several multiprotein complexes that regulate postinternalization signaling. 5, 6 The primary basis of current drug design toward GPCRs is the ligand binding site on the receptor. Better understanding and the ability to regulate the formation and/or localization of these signaling scaffolds may significantly improve future therapeutic interventions of many pathologies involving GPCRs. 7 The Transfluor ® assay is based on β-arrestin recruitment to activated GPCRs. A fusion of β-arrestin2:GFP was generated by Norak Biosciences, Inc. to allow image-based analysis of receptor internalization. Cells stably expressing the β-arrestin:GFP fusion can be transfected with the GPCR of interest and monitored by fluorescence microscopy for β-arrestin redistribution in response to receptor stimulation. The agonist-bound, activated GPCR/β-arrestin complex translocates to clathrin-coated pits on the plasma membrane where it can be observed forming bright green, fine puncta ("grains"). 8 Using image analysis, these pits can be quantified by a variety of parameters, including number, size, area, and fluorescence intensity. Similar to the formation of βarrestin-containing pits, the internalization and trafficking of the GPCR itself can also be monitored by immunofluoresence with an antibody toward the receptor. 9 Pits and/or vesicles containing the GPCR of interest can be quantified using similar sets of parameters as those used for the Transfluor ® assay.
We coupled a Transfluor ® assay and receptor internalization assay for a high-content imaging screen and identified lead molecules to develop inhibitor drugs targeting the GPCR of interest. Small molecules were identified affecting the localization of both β-arrestin and the GPCR itself. Finally, we present evidence that the multiplexed Transfluor ® and receptor internalization assays are an excellent predictor of compound activity in the in vitro biochemical assays. These data show the value of high-throughput screening and the rapidly evolving field of high-content screening in drug discovery and research. As possible decouplers of the expected agonist-induced trafficking and/or GPCR modulators, these molecules could be of great therapeutic benefit. 10
METHODS

Culture and cell lines
An U20S osteosarcoma cell line stably expressing a β-arrestin2:GFP fusion protein was obtained from Norak Biosciences (now Molecular Devices a part of MDS Inc., Mississauga, Ontario). In addition, cells were stably transfected with an expression vector for the GPCR of interest. Cells were cultured in minimum essential medium (MEM; Cellgro, Herndon, VA) and supplemented with 10% fetal bovine serum (FBS), 10 μg/mL gentamycin, 10 mM HEPES, 2 mM L-glutamine, 0.4 mg/mL G-418, and 1 μg/mL puromycin. Cells were cultured in a humidified incubator at 37 °C, 5% CO 2 .
Compound screening
Cells were seeded at 3000/well in 384-well plates, followed by 24-h incubation at 37 °C. Cells were washed twice with serum-free MEM (Cellgro) containing 0.25% bovine serum albumin (BSA; Sigma, St. Louis, MO) and treated with 12 μM of each compound for 30 min at 37 °C. Agonist was added to each well at EC 80 (1.52 nM) and incubated for an additional 30 min at 37 °C. Cells were fixed with 4% paraformaldehyde for subsequent processing. All compound treatments were performed in triplicate.
Immunofluorescence and image analysis
Following fixation, cells were processed for detection of the GPCR using standard immunofluorescence protocols compatible with the antibody used to this GPCR. 11 A Cy5-labeled secondary antibody (Jackson Immunologicals, West Grove, PA) was used to visualize the GPCR primary antibody, and the cell nuclei were counterstained with Hoechst 33342. Images were acquired on an INCell 3000 confocal imager using a 40X Nikon ELWD Plan Fluor/0.6 NA air objective. Images were analyzed with Raven software (GE Lifesciences, Piscataway, NJ) using the granularity (GRN01) and variable grain analysis modules. The granularity module was available from GE, and the variable grain module was developed within Merck. The variable grain algorithm is very similar in principle and analysis method to the recently available variable grain size algorithm from GE. The image analysis algorithms, using a nuclear marker, define an area around the nucleus where it identifies grains based on a user-defined size and fluorescence threshold. The mask generated by this image segmentation captures the formation of fluorescent "pits" and "vesicles" (aka grain) in the cells and assigns each grain to an individual nucleus (aka cell). Many image parameters were measured and collected; the one described here is F grains. An F grain is equal to 1000 * (sum of pixel intensity values in grains/sum of pixel intensity values in mask region).
Fluorometric imaging plate reader assay
The fluorometric imaging plate reader (FLIPR) assay used SKW6.4 cells overexpressing the GPCR of interest. Fluo-AM dye was loaded on the cells for 60 min at 37 °C. Cells were then treated with compound for 10 min, followed by stimulation with agonist for an additional 4 min. Plates were read on a FLIPR TETRA (MDS, Inc.).
Scintillation proximity assay binding assay
Binding of tritiated ligand to GPCR was performed with cell membranes obtained from Chinese hamster ovary (CHO) cells, overexpressing the GPCR of interest. Ligand concentration was at an approximate KD value, and membrane concentration was linear with time in assay buffer (50 mM HEPES, 10 mM MgCl 2 , 0.25% fatty acid-free BSA, and 5 mM D-glucose). Following equilibrium (2 h shaking at room temperature), binding was measured after incubating 30 min with wheat germ agglutinincoated scintillation proximity assay (SPA) beads (Amersham/GE Healthcare, Buckinghamshire, UK) and read in a 1450 MicroBeta TriLux (PerkinElmer, Waltham, MA). The reaction was initiated with the addition of membranes.
RESULTS AND DISCUSSION
Derivation of a cell line expressing both the β-arrestin2:GFP fusion and the GPCR of interest allowed a multiplexed GPCR inhibitor screening assay, including the ability to monitor GPCR fate. This multiparametric high-content imaging assay was able to profile small molecules as inhibitors, modulators, and, possibly, decouplers of receptor activation and β-arrestin binding and internalization. In untreated cells ( Fig. 1A, B , left panels), β-arrestin2:GFP was visible as diffuse green staining in the cytoplasm, whereas the GPCR signal was restricted primarily to the plasma membrane. A 30-min incubation of the cells with an agonist for the expressed GPCR ( Fig. 1A, B , right panels), followed by visualization, indicated that only a small proportion of β-arrestin localized to vesicles in the perinuclear region. During GPCR internalization, the majority of redistributed β-arrestin remained confined to coated pits. However, the stimulated GPCR fully internalized to vesicles localized in the perinuclear region. This was observed as minimal colocalization between β-arrestin and the GPCR of interest ( Fig. 1A, right  panel) . Due to the localization of β-arrestin and the GPCR to unique compartments, we used 2 separate algorithms to quantify β-arrestin redistribution and receptor internalization. β-arrestin localized to coated pits was quantified in the Transfluor ® assay using the granularity algorithm provided by Raven software with the INCell 3000 system (Fig. 1B) . This algorithm was ideally suited for this Transfluor ® assay as the β-arrestin2:GFP labels coated pits that are evenly spread and uniform in size and shape. After assessing several measurement parameters, we found that measuring the fraction of cellular fluorescence in the grains (F grains) correlated best with the known biology and acquired images (data not shown). Using F grains for quantification, the assay window (presence vs. absence of agonist) was approximately 7. In the presence of a control antagonist, the agonistinduced translocation was ablated in a dose-dependent manner ( Fig. 1C and data not shown).
The Transfluor ® assay was quantified using the granularity algorithm because the β-arrestin2:GFP redistributed to a puncta pattern of uniform size and distribution. However, upon activation, this GPCR localized to vesicle-like structures in the perinuclear region, likely the recycling compartment, with varying size and shape. To appropriately quantify internalization of this GPCR, we used a proprietary algorithm for the INCell 3000 developed for this application (see Methods for further details). This algorithm, referred to as "variable grain," allows quantification of variably sized grains within different cellular compartments, such as the vesicle-like structures observed in these cells ( Fig. 1D) . Although the 3.5-fold window (presence vs. absence of agonist) is slightly less than for Transfluor ® , it is well above the assay window measured for many biological responses. Indeed, using the variable grain algorithm for the receptor internalization assay was robust and reliable. Measurement of agonist-induced internalization of this GPCR, in the presence of a known antagonist, produced a dose-dependent response similar to the Transfluor ® assay and consistent with other assays (e.g., radioligand binding; Fig. 1E and data not shown). Development and utilization of these 2 algorithms allowed accurate quantification of different subcellular localization events. Identification of compounds blocking both Transfluor ® and receptor internalization would be expected to have a higher probability of blocking receptor activity itself. Thus, multiplexing the Transfluor ® assay and receptor internalization can give greater confidence in the biological phenotypes observed.
A calcium release assay (FLIPR) as a primary screen identified approximately 2000 small-molecule compounds blocking the activity of the GPCR of interest. To further characterize these compounds, we performed a high-content screen. The highcontent assay identified 377 compounds that altered normal relocalization and internalization of either β-arrestin or this GPCR. These compounds could be divided into 3 categories: those that affect the Transfluor ® assay, those affecting receptor internalization, and compounds affecting both processes ( Fig. 2A) . Hits were chosen based on the global mean +3 sigma cutoff values of 17% and 24% inhibition for the Transfluor ® assay and receptor internalization assay, respectively. The distribution of small-molecule hits is shown in Figure 2B . Compounds found at the intersection of all 4 categories (Fig. 2B) showed good correlation between the Transfluor ® and receptor internalization assays but were classified as affecting only β-arrestin redistribution or only receptor internalization due to application of cutoff values (Fig.  2B , large light blue arrows). If the hit selection cutoff values were lowered, many of those compounds affecting β-arrestin or receptor internalization alone would be reclassified as hits in both categories. Although the majority of hits in this imaging assay show good correlation between blocking Transfluor ® and receptor internalization, there were several outliers that clearly segregate away from the diagonal (R 2 value = 0.7), showing activity only in the Transfluor ® or only the receptor internalization assays (Fig. 2B ; indicated by dark blue arrows). These compounds warranted closer inspection to determine why the results in the 2 assays did not correlate.
Compounds away from the diagonal and outside normal distribution were found to have unique characteristics or induce unusual phenotypes (Fig. 3) . Activation of this class A GPCR results in β-arrestin localized to coated pits, whereas the receptor itself is localized to vesicle-like structures ( Fig. 3Ai + + ii) . In the presence of a full antagonist, β-arrestin redistribution is completely blocked, and the receptor remains entirely on the cell surface ( Fig. 3Bi + + ii) . Several compounds were found to be false negatives due to autofluorescence in the green channel and were initially eliminated as hits from the Transfluor ® assay. However, this compound showed a 50% block of receptor internalization and was rescued by the receptor internalization assay. The compound illustrated in Figure 3C is 1 example of an autofluorescent compound. Conversely, by assessing both β-arrestin and receptor redistribution, we were able to eliminate false-positive autofluorescent compounds identified in the primary FLIPR screen and whose activity toward the GPCR could not have been established by the Transfluor ® assay alone. This type of multiplexed, functional assay provides excellent ability to rescue autofluorescent compounds that show true inhibition of receptor internalization.
Several compounds were found to redirect either β-arrestin or the receptor to cellular compartments other than those typically observed. In 1 case, the receptor is directed toward the normal vesicle-like structures, but β-arrestin is also directed toward these structures, rather than remaining in coated pits ( Fig. 3Di + + ii) . This phenotype was identified because the vesicle-like structures containing β-arrestin were not recognized by the granularity algorithm, due to their variable size and shape. Thus, the algorithm identified this compound as inhibiting the Transfluor ® assay (72% inhibition). However, the vesicle-like structures of the receptor were identified as normal internalization with no inhibition. In fact, there appeared to be a slight increase in receptor internalization showing -10% inhibition. Using these 2 assays, this compound was found to redirect β-arrestin localization while maintaining normal receptor internalization. This compound could therefore act as modulator of the GPCR because changing the GPCR-arrestin interaction induces an arrestin-containing signaling complex in the endosomal compartment and did not result in calcium mobilization in the FLIPR assay. The converse is true in another phenotype identified: here the receptor was blocked in presumed coated pits, with normal redistribution of β-arrestin ( Fig.  3Ei + + ii) . The granularity algorithm identifies β-arrestin in coated pits as normal redistribution with no inhibition of the assay. However, the variable grain algorithm was unable to accurately identify the receptor in uniformly sized coated pits. Because the variable grain algorithm is unable to identify the receptor in coated pits, the algorithm quantifies this as inhibition of receptor internalization (65% inhibition of internalization). Coupling both the FLIPR results showing a blockage of agonist-induced calcium release and the imaging results showing that the receptor is trapped in coated pits indicates that the signaling cascade was interrupted downstream of GPCR phosphorylation but upstream of phospholipase C (PLC) activation. By acting as GPCR uncouplers or partial agonists, this class of compounds could overcome receptormediated desensitization, a limit to drug efficacy observed in chronic therapies. 10 Several drugs have been recently recognized as exerting their therapeutic effects through redirecting a pathway's signaling elements. 12, 13 As our understanding of cellular signaling increases, more small molecules will be identified that use a similar mechanism of action. 7, 14 Similarly, another compound identified induces a phenotype allowing β-arrestin redistribution to the plasma membrane but blocking receptor internalization ( Fig.  3Fi + + ii) . Both β-arrestin and GPCR are observed at the plasma membrane in a diffuse pattern and minimal localization in pits, consistent with the observed 62% inhibition of receptor internalization. This phenotype suggests the decoupling of receptor desensitization (indicated by the recruitment of arrestin) from receptor sequestration. Only this multiplexed analysis could identify these pharmacologically interesting phenotypes. In addition to possible novel classes of GPCR modulators, the compounds inducing these phenotypes serve as ideal tools for studying β-arrestin and receptor trafficking.
High-Content Imaging for Assessment of GPCR Activity
A subset of these small molecules with strong activity in both the Transfluor ® and receptor internalization assays was further tested in a competitive SPA binding assay. This SPA assay provides a direct biochemical measure of the compound's ability to block ligand-receptor interaction. The ability of each compound to inhibit agonist binding, receptor internalization, Transfluor ® , and FLIPR activity was compared ( Fig. 4) . Analysis of the relationship between the imaging assays and SPA binding shows an excellent relationship between these assays (R 2 value = 0.5). Those compounds showing greater inhibition of agonist binding in the SPA assay also showed excellent inhibitory activity in the imaging assays. This is represented by similar colored boxes being grouped together ( Fig. 4) , with the red boxes positioned as the strongest inhibitors in all 3 assays. Interestingly, a comparison of inhibition in the FLIPR assay (shown by box size) showed relatively poor correlation with the imaging results and SPA assays. Compounds of a given activity in the FLIPR assay are distributed across the scatterplot rather than being grouped together in a correlative fashion with the Transfluor ® (R 2 value = 0.023), receptor internalization (R 2 value = 0.002), or SPA assays (R 2 value = 0.021). Although both the imaging and FLIPR assays are functional assessments of GPCR signaling, the imaging assays provide more detailed mechanistic information. In addition, the FLIPR assay is not predictive of a compound's antagonistic activity at the level of receptor-ligand interaction, but the imaging assays are predictive. These data suggest that a multiplexed imaging assay for this GPCR is a good estimation of direct biochemical inhibition and might be used for compound SAR. Additional testing needs to be performed to determine whether this correlation is an isolated case and whether it is general feature of GPCRs or only certain classes of GPCRs. By using high-content imaging, we have provided a means to eliminate false positives and rescue false negatives. We have identified a variety of compounds that elicit interesting phenotypes. These compounds may represent novel classes of modulators, partial agonists, or decouplers for this GPCR. 14 Certainly, they will be good tools to study this GPCR and, perhaps, GPCR trafficking in general. Finally, we have found that a direct biochemical binding assay shows better correlation with the imaging assays than the FLIPR assay, and the imaging assays provide a context for interpretation of the otherwise non-target-specific FLIPR data.
